Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

SAN DIEGO and TORONTO, Jan. 30, 2023. Aptose Biosciences Inc. (“Aptose”) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials